Paul Y. Song, MD is Chairman and CEO of NKGen Biotech. He was a Co-Founder and CEO of Fuse Biotherapeutics which was acquired in 2025 by Johnson & Johnson. He is also on the board of PeproMeme Bio and Hawkeye Bio.
Dr. Song’s last clinical role was Asst. Professor at the Samuel Oschin Cancer Center at Cedars Sinai Medical Center.
He is currently on the advisory board of the Pritzker School of Molecular Engineering at the University of Chicago and a board member of Prosper Global (formerly Mercy Corps) and Gideon’s Promise.
Dr. Song graduated with honors from the University of Chicago and received his M.D. degree from George Washington University. He completed his residency in radiation oncology at the University of Chicago where he served as Chief Resident and did a brachytherapy fellowship at the Institute Gustave Roussy in Villejuif, France. He was also awarded an ASTRO research fellowship in 1995 for his research in radiation inducible gene therapy.

Dr. Song served as the very first visiting fellow on healthcare policy in the California Department of Insurance in 2013.

His late grandfather, Kim Sang Don, was the first democratically elected mayor of Seoul, South Korea.